Tiotropium Respimat inhaler and the risk of death in COPD

Robert A Wise, Antonio Anzueto, Daniel Cotton, Ronald Dahl, Theresa Devins, Bernd Disse, Daniel Dusser, Elizabeth Joseph, Sabine Kattenbeck, Michael Koenen-Bergmann, Gordon Pledger, Peter Calverley, TIOSPIR Investigators, Lorcan McGarvey

Research output: Contribution to journalArticlepeer-review

286 Citations (Scopus)


Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.
Original languageEnglish
Pages (from-to)1491-501
Number of pages11
JournalNew England Journal of Medicine
Issue number16
Publication statusPublished - 17 Oct 2013


  • Administration, Inhalation
  • Aged
  • Aged, 80 and over
  • Bronchodilator Agents
  • Double-Blind Method
  • Female
  • Forced Expiratory Volume
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Nebulizers and Vaporizers
  • Pulmonary Disease, Chronic Obstructive
  • Risk
  • Scopolamine Derivatives
  • Spirometry


Dive into the research topics of 'Tiotropium Respimat inhaler and the risk of death in COPD'. Together they form a unique fingerprint.

Cite this